L4I Logo
  • Emerging Infections
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • GESI
  • LEARNING LIBRARY
  • Primary Healthcare

This section hosts guidelines, manuals and toolkits to strengthen public health practice.

Resources

FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E
Emerging Pandemics

Does the World Still Need New COVID-19 Vaccines?

23 May 2022

Despite a global scarcity of Covid-19 vaccinations in 2021, the vaccine supply will no longer be a restricting factor in efforts to deliver more equitable coverage by the middle of 2022. A total of 344 vaccine candidates for Covid-19 have been produced or are currently being researched. After conditional clearance by national regulatory agencies or under the WHO Emergency Use Listing, 31 vaccination products are already in widespread use. There have been at least five different technology platforms deployed. “So why new Covid-19 vaccinations are still required?” The Covid-19 vaccinations that were first utilized during the epidemic may not be the best long-term option. To give cross-immunity against SARS-CoV-2 variants, the next generation of Covid-19 vaccines will need to have larger epitope coverage, confer a longer length of protection, and be easy to update in a timely manner for protection against any new variants. By accepting trade-offs, we should stay flexible in fine-tuning the optimum use of Covid-19 vaccines for the greatest impact on global public health. With more vaccination platforms accessible, we may be able to improve vaccine selection decision-making, as different vaccine platforms may be more suited to different age groups, subpopulations, and pregnant women. To maximize the benefits of each of these platforms, we may need to mix and blend vaccinations more frequently. Finally, currently available vaccinations are only somewhat effective against mild infection and transmission, which is further hampered by the emergence of novel omicron sub types. As a result, new vaccines that have a significant effect on lowering mild infection and transmission are needed to restrict the virus's spread and limit the speed at which new varieties evolve, even as the world tries to learn how to live with SARS-CoV-2.9.

To read the full article, please download the linked file. 


Download PDF
PUBLISHED BY
The New England Journal of Medicine
YEAR OF PUBLISHING
2022
AUTHORS
Hanna Nohynek, M.D., et al.

Categories

COVID-19
KEY ORGANIZATIONS

FOLLOW US

  • HOME
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
  • LEARNING LIBRARY
  • ABOUT US
  • CONTACT US
  • PRIVACY POLICY
Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2023 Swasti Health Catalyst

Get the latest!

Learning4impact provides a wealth of resources to support your public health work or research.

Sign up to get latest resources on public health!

Submit Feedback

Download Now

Yes, Subscribe me to the Learning4impact newsletter!
  • EMERGING INFECTIONS
  • THEMES
  • USAID INVESTMENTS
  • SPECIAL FOCUS AREAS
    • Corporate TB Pledge
    • Urban Health
    • Inclusive Development
  • LEARNING LIBRARY
  • Primary Healthcare